News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%John Patrick Darby, EVP and general counsel of Encompass Health Corporation (NYSE:EHC), sold 8,906 shares of common stock on August 10, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold (directly held) 8,906 Transaction value $1.1 million Post-transaction shares (directly …
Douglas E. Coltharp, EVP and chief financial officer of Encompass Health Corporation (NYSE:EHC), sold 18,869 shares of common stock on August 10 for a total transaction value of approximately $2.4 million, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold …
Encompass Health Corporation (NYSE:EHC) President and CEO Mark J. Tarr reported a sale of about 173,000 shares of common stock on August 10, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction date August 10, 2026 Shares sold 173,148 Transaction …
Xencor, Inc. reported a mixed financial performance for Q2 2026, showing a reduced net quarterly loss of US$21.73 million, yet an expanded net loss of US$150.65 million for the first half of the year. This disparity suggests uneven cost management, prompting investors to consider …
This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. …
Oppenheimer Asset Management Inc. has acquired a new position in Cadence Design Systems, Inc. (NASDAQ:CDNS), purchasing 14,454 shares valued at approximately $5.425 million during the second quarter. This move aligns with several other institutional investors who have also adjusted their holdings in the software …
Maridea Wealth Management LLC has made a new investment in Cadence Design Systems (NASDAQ:CDNS), purchasing 8,147 shares valued at approximately $3.06 million in the second quarter. Despite recent insider selling totaling $54.6 million, institutional investors hold 84.85% of the stock. Analysts maintain a "Moderate …
Gilead Sciences is partnering with Nucleai for AI-powered tissue analytics to enhance its antibody-drug conjugate (ADC) clinical development and precision oncology efforts. This collaboration supports Gilead's long-term strategy to pivot into oncology, leveraging its strong HIV core business. However, despite the potential of AI-enabled …
Summit Global Investments initiated a new position in Gilead Sciences, acquiring 11,712 shares valued at $1.48 million during the second quarter. Gilead Sciences reported strong Q2 earnings, surpassing revenue and EPS expectations, with a 10.6% year-over-year revenue increase and declared a quarterly dividend of …
Centric Wealth Management has acquired a new stake of 26,506 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $3.52 million during the second quarter. This move is part of broader institutional interest, with 83.67% of Gilead's stock owned by institutional investors and hedge …
Quantinno Capital Management LP significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 387.3% in the first quarter, acquiring an additional 36,144 shares. This brings their total holdings to 45,476 shares, valued at approximately $1.12 million. While institutional investors own a large portion …
Cornerstone Capital Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 36,158 shares valued at approximately $4.57 million during the second quarter. This move comes as institutional investors and hedge funds collectively own 83.67% of the company. Gilead recently reported stronger-than-expected quarterly …
Bank Hapoalim BM has invested $1.78 million in Edwards Lifesciences Corporation by purchasing 19,640 shares. This comes as other institutional investors have also adjusted their holdings in the medical research company. Analysts maintain a "Moderate Buy" rating for Edwards Lifesciences, with a consensus target …
Bank Hapoalim BM recently purchased 4,924 shares of Cadence Design Systems, Inc. (NASDAQ:CDNS) valued at approximately $1.85 million. This institutional investment is part of a broader trend, as several other institutional investors also increased or initiated positions in CDNS during recent quarters. The software …
ABN AMRO Bank N.V. has acquired a new stake of 100,168 shares in Cadence Design Systems, Inc. (NASDAQ:CDNS) during the second quarter, valued at approximately $37.37 million. This purchase is part of broader institutional investment activity in CDNS, with several other large investors also …
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript Operator: Hello, and thank you for standing …
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …
Cencora (COR) recently reported strong Q3 2026 results with $84.75 billion in sales and $763.52 million in net income, alongside declaring a $0.60 quarterly dividend. The company also expanded its multi-currency credit facility to $7.00 billion with maturities extended to 2031, reinforcing its financial …
Xencor, Inc.'s revenue estimates have been significantly upgraded by analysts, signaling increased optimism for the company's future performance. This positive revision comes despite the company not having current revenues, as analysts anticipate strong growth. The upgraded forecasts suggest a bright outlook for Xencor, Inc. …
Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …
Search by ticker symbol or company name and select a result to open its chart.